A blood test built to spot signals from more than 50 different cancers in a single draw is going before the US Food and Drug Administration this week.
The test is called Galleri, developed by the California company GRAIL, and on September 23, 2026, the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will review its Premarket Approval application.
If cleared, Galleri would become the first multi-cancer early detection test to win formal FDA approval. Today it is sold only as a lab-developed test under CLIA rules, by prescription, and has not been cleared or approved by the FDA.
50-cancer test
Galleri does not look for tumors themselves. It reads chemical tags called methylation patterns on fragments of DNA that leak from cells into the bloodstream.
Also read: Your waist measurement may reveal how vulnerable you are to everyday air pollution
Cancer cells leave a different pattern than healthy cells, and different cancers leave different fingerprints, so a machine-learning model can flag a cancer signal and point to the organ it most likely came from.
The test is designed to add to, not replace, existing screening for breast, cervical, colorectal, lung and prostate cancer.
Its intended payoff sits with the many cancers that have no routine screening at all, including pancreatic, ovarian, liver and esophageal disease, where most patients are diagnosed only after symptoms appear.
The evidence the FDA panel will weigh
The submission is anchored in the PATHFINDER 2 study, a prospective trial across the United States and Canada in adults aged 50 and older with no clinical suspicion of cancer.
Also read: How your weekly egg habit may quietly shape your Alzheimer's risk after 65
Results presented at the 2026 ASCO Annual Meeting from 35,878 participants showed the Galleri test increased screen-detected cancers roughly 6.5-fold when added to standard USPSTF-recommended screening, with 99.6 percent specificity, a positive predictive value of 60.3 percent, and cancer signal origin accuracy of 91.3 percent.
About 53 percent of new cancers were caught at stage I or II.
The FDA package itself is built on the 25,490 participants with one year of follow-up from the same PATHFINDER 2 dataset, plus more than 70,000 people from the intervention arm of the NHS-Galleri trial in England, the largest randomized controlled trial of a multi-cancer test to date.
GRAIL submitted the Premarket Approval application on January 29, 2026, and the test has held FDA Breakthrough Device designation since 2018.
Also read: Whether you are the oldest or youngest sibling may shape which diseases you develop
A positive result is not a diagnosis. In PATHFINDER 2, when Galleri flagged a signal, cancer was confirmed in about six of every ten cases, so a positive test triggers imaging or biopsy rather than treatment.
Roughly 0.6 percent of participants ended up needing an invasive diagnostic procedure, and the median time to a diagnostic answer was 48 days.
What FDA approval would change
Right now the price is a barrier. GRAIL lists Galleri at $949, with a self-pay price of $799 through many providers, and the test is not covered by Medicare or most private insurance, though TRICARE has begun offering it to eligible military beneficiaries aged 50 and older with elevated cancer risk.
An FDA nod would not by itself force insurers to pay, but it would move the test from lab-developed status into the same regulatory bracket as approved diagnostics, opening the door to a Medicare coverage decision and to broader private-payer reimbursement.
Also read: These celebrities kept their cancer diagnoses out of the public eye
The September 23 meeting is a recommendation, not a final ruling. The FDA is not bound by the panel's vote, but usually follows it, and the agency's decision on the Premarket Approval application will come later.
Anyone with a family history of cancer, unexplained symptoms or questions about whether an MCED test fits their personal risk should talk with their own doctor before ordering it.
Also read: A new blood test for colorectal cancer just got FDA approval - who should get it?
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.